- LY3200882
-
- $39.00 / 1mg
-
2026-03-13
- CAS:1898283-02-7
- Min. Order:
- Purity: 99.63%
- Supply Ability: 10g
|
| | 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol Basic information |
| Product Name: | 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol | | Synonyms: | 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol;LY-3200882;2-[4-[[4-[1-cyclopropyl-3-(oxan-4-yl)pyrazol-4-yl]oxypyridin-2-yl]amino]pyridin-2-yl]propan-2-ol;CS-2805;2-Pyridinemethanol, 4-[[4-[[1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy]-2-pyridinyl]amino]-α,α-dimethyl-;4-[[4-[[1-Cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy]-2-pyridinyl]amino]-α,α-dimethyl-2-pyridinemethanol;Anti-cancer,ALK5,TGFβRI,ATP-competitive,inhibit,immune,phosphorylation,Transforming growth factor beta receptors,anti-metastatic,LY 3200882,TGF-β Receptor,LY-3200882,SMAD,serine-threonine,LY3200882,Inhibitor;LY-3200882 (LY3200882) | | CAS: | 1898283-02-7 | | MF: | C24H29N5O3 | | MW: | 435.52 | | EINECS: | | | Product Categories: | | | Mol File: | 1898283-02-7.mol |  |
| | 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol Chemical Properties |
| Boiling point | 607.2±55.0 °C(Predicted) | | density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:108.5(Max Conc. mg/mL);249.12(Max Conc. mM) | | form | A crystalline solid | | pka | 13.45±0.29(Predicted) | | color | Off-white to light yellow |
| | 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol Usage And Synthesis |
| Uses | 4-[[4-[[1-Cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy]-2-pyridinyl]amino]-α,α-dimethyl-2-pyridinemethanol is used to prepare aminopyridyloxypyrazole compounds as TGFβR1 inhibitors. | | in vivo | LY3200882 (60 mg/kg; oral gavage; twice a day; for 21 days; BALB/C female mice) treatment significantly delays tumor growth in CT26 model[2].
LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose dependent fashion[1].
LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer)[1]. | Animal Model: | BALB/C female mice (5-8-week-old) injected with CT26 cells[2] | | Dosage: | 60 mg/kg | | Administration: | Oral gavage; twice a day; for 21 days | | Result: | A statistically significant tumor growth delay in CT26 model was observed.
|
|
| | 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol Preparation Products And Raw materials |
|